JOURNAL TOPICS NEWSPAPERSBusiness Directories,Company Directories

Company Name: Corporate Name:	JOURNAL & TOPICS NEWSPAPERS
Company Title:
Company Description:
Keywords to Search:
Company Address:	Po Box 147,DUNDEE,MI,USA
ZIP Code: Postal Code:	60016-4556
Telephone Number:	8472988549 (+1-847-298-8549)
Fax Number:	8472995511 (+1-847-299-5511)
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	3694
USA SIC Description:	Electrical Equipment for Internal Combustion Engines
Number of Employees:
Sales Amount:
Credit History: Credit Report:
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
DUNDEE INTERNET SVC INC
DIAMOND ELECTRIC MFG CORP
UNITED BANK & TRUST

Next company profile:
YOUNGS INC
DENNIS MORRIS INSURANCE AGENCY
CARPENTER TECHNOLOGY CORP

Company News:

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Preclinical and observational studies suggest that exercise may improve cancer outcomes However, definitive level 1 evidence is lacking In this phase 3, randomized trial conducted at 55 centers,
Tirzepatide for Heart Failure with Preserved Ejection Fraction and . . .
GLP-1RA versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: An updated meta-analysis of randomized controlled trials, International Journal of
Coadministered Cagrilintide and Semaglutide in Adults with Overweight . . .
A total of 3417 participants underwent randomization, with 2108 assigned to receive cagrilintide–semaglutide, 302 to receive semaglutide, 302 to receive cagrilintide, and 705 to receive placebo
Zongertinib in Previously Treated - The New England Journal of Medicine
In cohort 1, a total of 75 patients received zongertinib at a dose of 120 mg At the data cutoff (November 29, 2024), 71% of these patients (95% confidence interval [CI], 60 to 80; P<0 001 against
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or progressed during or after
Mitochondrial Donation and Preimplantation Genetic Testing for mtDNA . . .
Clinical pregnancies were confirmed in 8 of 22 patients (36%) and 16 of 39 patients (41%) who underwent an intracytoplasmic sperm injection procedure for pronuclear transfer or for PGT, respectively
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A . . .
We conducted a phase 2, double-blind, randomized, placebo-controlled, dose-ranging trial that included 11 groups as two cohorts Participants with obesity (obesity cohort) were randomly assigned
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Despite treatment advances in lupus nephritis, including regulatory approvals of belimumab and voclosporin, 1,2 the goal to sufficiently improve short- and long-term outcomes in patients with
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes
Of 12,821 patients (6414 patients in the intensive-treatment group and 6407 in the standard-treatment group) enrolled from February 2019 through December 2021, 5803 (45 3%) were women; the mean
Clinical Practice Topics - The New England Journal of Medicine
LOOKING FOR SPECIALTIES? VIEW SPECIALTIES ARTICLE CATEGORIES Research; Reviews; Clinical Cases; Perspective; Commentary; Other